Loading...
XNAS
PAVMZ
Market cap10mUSD
Apr 30, Last price  
0.00USD
Name

PAVmed Inc

Chart & Performance

D1W1MN
P/E
0.00
P/S
0.00
EPS
1,848.32
Div Yield, %
—
Shrs. gr., 5y
36.88%
Rev. gr., 5y
%
Revenues
3.00b
+122,045.19%
0000000500,000377,0002,452,0002,995,000,000
Net income
31.97b
P
-548,768-1,776,600-5,650,851-9,519,269-17,968,750-15,931,309-34,329,000-50,347,000-101,294,000-64,175,00031,966,000,000
CFO
-33.55b
L+64,382.28%
-60,270-1,249,605-4,454,857-6,608,208-8,787,907-13,357,271-21,914,000-40,591,000-70,985,000-52,036,000-33,554,000,000
Earnings
Aug 11, 2025

Profile

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
URL
https://pavmed.com/
IPO date
Jul 27, 2016
Employees
124
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,995,000
122,045.19%
2,452
550.40%
377
-24.60%
Cost of revenue
46,923,000
69,226
89,520
Unusual Expense (Income)
NOPBT
(43,928,000)
(66,774)
(89,143)
NOPBT Margin
Operating Taxes
(3,539,000)
(1,944)
Tax Rate
NOPAT
(40,389,000)
(66,774)
(87,199)
Net income
31,966,000
-49,910.67%
(64,175)
-36.64%
(101,294)
101.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,951
1,817
1,520
BB yield
Debt
Debt current
29,613
45,765
34,791
Long-term debt
5,007
7,485
4,833
Deferred revenue
Other long-term liabilities
Net debt
(1,150,380)
33,611
(120)
Cash flow
Cash from operating activities
(33,554,000)
(52,036)
(70,985)
CAPEX
(242)
(1,540)
Cash from investing activities
(16,184,000)
758
(4,740)
Cash from financing activities
31,284,000
31,173
38,211
FCF
(9,763,581)
(67,336)
(91,102)
Balance
Cash
1,185,000
19,639
39,744
Long term investments
Excess cash
1,035,250
19,516
39,725
Stockholders' equity
(254,966,211)
(261,618)
(204,764)
Invested Capital
250,209,824
286,325
252,335
ROIC
ROCE
923.56%
EV
Common stock shares outstanding
9,672
7,232
5,938
Price
Market cap
EV
EBITDA
(43,926,802)
(63,842)
(86,686)
EV/EBITDA
Interest
45,000
589
1,272
Interest/NOPBT